After 15 years of research, researchers from the Regional Hospital in Málaga and the Institute of Biomedical Research of Málaga have developed a medication to treat Fragile X Syndrome. The European Medicines Agency has granted orphan drug status to this product, with 65% effectiveness in the clinical trial carried out.